Company news
Aligos Therapeutics, Inc. (NASDAQ:ALGS) news
Aligos Therapeutics, Inc. news releases on 6ix. Latest, Jun 22, 2022: Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data…
Press releases — page 3
Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European...
June 21, 2022
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
May 3, 2022
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
April 26, 2022
Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development
April 3, 2022
Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio
March 21, 2022
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
March 9, 2022
Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022
March 1, 2022
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)
January 25, 2022
Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH
January 10, 2022
Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133
January 5, 2022
Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study
December 8, 2021
Aligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors
November 17, 2021
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results
November 3, 2021
Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021
October 27, 2021
Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study
October 10, 2021
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
August 4, 2021
Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
July 28, 2021
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
June 29, 2021
Aligos Therapeutics Announces Proposed Public Offering of Common Stock
June 27, 2021
Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital Internationa...
June 20, 2021
Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
June 13, 2021
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results
May 9, 2021
Aligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021
May 4, 2021
Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors
April 26, 2021
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
April 13, 2021
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
March 22, 2021
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
March 9, 2021
Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH
December 6, 2020
Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD’s The Liver Meeting Digital Experience™ 2020
November 15, 2020
Aligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference
November 12, 2020
Aligos Therapeutics is awarded €1.8M VLAIO grant to advance chronic hepatitis B research
November 11, 2020
Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B
October 29, 2020
Aligos Therapeutics Announces Pricing of Initial Public Offering
October 14, 2020